Bisulfite profiling of the MGMT promoter and comparison with routine testing in glioblastoma diagnostics.

ABSTRACT:

Background

Promoter methylation of the DNA repair gene O⁶-methylguanine-DNA methyltransferase (MGMT) is an acknowledged predictive epigenetic marker in glioblastoma multiforme and anaplastic astrocytoma. Patients with methylated CpGs in the MGMT promoter benefit from treatment with alkylating agents, such as temozolomide, and show an improved overall survival and progression-free interval. A precise determination of MGMT promoter methylation is of importance for diagnostic decisions. We experienced that different methods show partially divergent results in a daily routine. For an integrated neuropathological diagnosis of malignant gliomas, we therefore currently apply a combination of methylation-specific PCR assays and pyrosequencing.

Results

To better rationaliz

SUBMITTER: Tierling S 

PROVIDER: S-EPMC8857788 | biostudies-literature | 2022 Feb

REPOSITORIES: biostudies-literature